ESSEX, UK, Aug 14, 2025 – Europlaz has invested more than £700,000 over the last six years into ‘greening’ its manufacturing operations and making a positive impact on the communities it operates in.
The company has obtained ISO:14001 environmental accreditation and generates up to 68% of its energy from solar panels. It has also set a target to achieve net-zero emissions by 2045, aligning with NHS requirements.
Ellie Harrington, sustainability officer at Europlaz, commented: “We are proud to manufacture products that save lives and want to extend this philosophy by making sure we have a positive Environmental, Social and Governance strategy (ESG) in place.”
“This got underway six years ago, but the last twelve months have seen us really accelerate our investment in this area as we can see the difference it is making to our environmental footprint, the wellbeing of our staff and the sectors we operate in.”
She continued: “For the first time ever, we have managed to calculate the carbon footprint of a product we manufacture. TIVA (Total Intravenous Anesthesia Sets) involves production and two-stage assembly – we’ve completely mapped the process so that we can look at ways where we can minimize waste, reduce energy and ultimately cut the carbon footprint involved.”
“This is just the start, and we hope to create the greenest anesthetist product ever made. We’ve now got another six products we’re looking to do the same for.”
Europlaz, which is ISO:13485-certified, operates from ‘The Maltings Industrial Estate’ in Southminster, near Chelmsford.
From here, the family-run business has invested £4m into creating a facility capable of injection molding, assembly, product validation and access to modern cleanrooms, all certified to ISO Class 7 for the manufacture of Class I, Class II and Class III medical devices.
Most of its work is focused on helping medical device and healthcare businesses commercialize new technology, with success stories featuring a home dialysis machine, an easy-to-use breath operated inhaler and a bio-artificial liver.
Ellie concluded: “Sustainability is a win-win. We know we are measuring and refining our production processes so that we can manufacture as green as we can.”
“It also means we are meeting domestic and global healthcare standards, and this is already paying off. So far, we believe this approach has resulted in £650,000 of new work that we previously would have been excluded from.”
About Europlaz
Europlaz Technologies Ltd., founded in 2000 and headquartered in Southminster, Essex, is a UK-based contract manufacturer specializing in ISO 13485-certified medical device production. The company serves the diagnostic, drug delivery, life sciences, and biomedical sectors, providing services such as rapid prototyping, injection molding, cleanroom assembly, validation, sterile packaging, and third-party logistics. Operating from its Southminster facility with over 110 people, Europlaz completed a £3.5M investment program to expand cleanroom capacity, support a 20% sales increase, and secure new contracts with medical device clients in the UK and internationally. Its production capabilities cover Class I to Class III devices. The financial filings of Europlaz for the fiscal year ending March 2024 report turnover of approx. £12M, or about $15M.